{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-028622","form_type":"8-K","ticker":"CTXR","cik":"0001506251","company_name":"Citius Pharmaceuticals, Inc.","filed_at":"2025-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.523088+00:00","generated_at":"2026-05-23T22:31:28.081872+00:00","sec_items":["1.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Citius Oncology amends license agreement with Eisai, defers $8.2M in LYMPHIR payments to 2025","bullets":["Total obligations owed to Eisai: $8,233,209.77 including $5.9M milestone and $2.33M development/inventory costs.","Payment schedule: $2,535,317.77 by July 15, 2025; four monthly $2.35M payments; final $2,197,892.07 by Dec 15, 2025.","Interest at 2% per annum on delayed amounts from original due dates.","Parties released each other from claims related to late payment of milestone and other costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-028622","json":"https://secwatch.observer/filing/0001213900-25-028622.json","markdown":"https://secwatch.observer/filing/0001213900-25-028622.md","text":"https://secwatch.observer/filing/0001213900-25-028622.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506251/000121390025028622/0001213900-25-028622-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506251/000121390025028622/ea0237093-8k_citius.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T22:31:28.081872+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}